Benitec Biopharma annual return on equity
2020
2021
2022
2023
2024
2025
Benitec Biopharma Return on Equity (ROE) Growth & History (BNTC)
Benitec Biopharma's return on equity was −52.46% for fiscal 2025.
View full Benitec Biopharma company overviewBenitec Biopharma annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-06-30 | −52.46% | +39.21 pp |
| 2024 | 2024-06-30 | −91.68% | +1176.93 pp |
| 2023 | 2023-06-30 | −1,268.61% | −1109.53 pp |
| 2022 | 2022-06-30 | −159.08% | −67.29 pp |
| 2021 | 2021-06-30 | −91.79% | −30.12 pp |
| 2020 | 2020-06-30 | −61.67% | — |
Benitec Biopharma quarterly return on equity
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q3 2026 | 2026-03-31 | −6.44% | +10.28 pp |
| Q2 2026 | 2025-12-31 | −8.43% | +5.21 pp |
| Q1 2026 | 2025-09-30 | −9.39% | −0.31 pp |
| Q4 2025 | 2025-06-30 | −9.04% | +7.03 pp |
| Q3 2025 | 2025-03-31 | −16.71% | +15.02 pp |
| Q2 2025 | 2024-12-31 | −13.63% | +22.36 pp |
| Q1 2025 | 2024-09-30 | −9.08% | +43.82 pp |
| Q4 2024 | 2024-06-30 | −16.07% | +173.60 pp |
| Q3 2024 | 2024-03-31 | −31.73% | +32.43 pp |
| Q2 2024 | 2023-12-31 | −35.99% | +9.85 pp |
| Q1 2024 | 2023-09-30 | −52.90% | +5.32 pp |
| Q4 2023 | 2023-06-30 | −189.66% | −92.24 pp |
| Q3 2023 | 2023-03-31 | −64.16% | −28.47 pp |
| Q2 2023 | 2022-12-31 | −45.84% | −9.20 pp |
| Q1 2023 | 2022-09-30 | −58.22% | −29.79 pp |
| Q4 2022 | 2022-06-30 | −97.42% | −71.55 pp |
| Q3 2022 | 2022-03-31 | −35.68% | −5.09 pp |
| Q2 2022 | 2021-12-31 | −36.65% | −7.56 pp |
| Q1 2022 | 2021-09-30 | −28.43% | +1.81 pp |
| Q4 2021 | 2021-06-30 | −25.88% | −4.00 pp |
| Q3 2021 | 2021-03-31 | −30.59% | — |
| Q2 2021 | 2020-12-31 | −29.09% | — |
| Q1 2021 | 2020-09-30 | −30.24% | — |
| Q4 2020 | 2020-06-30 | −21.88% | — |
Benitec Biopharma return on equity trends
Over the last five fiscal years, Benitec Biopharma's return on equity increased from −61.67% to −52.46%, a change of +9.21 percentage points. The latest reported quarter, Q3 2026, shows −6.44%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Benitec Biopharma source filings ↗